Conatus to Slash Staff, Consider Sale After NASH Trial Failures

Conatus Pharmaceuticals said Monday that it would cut its staff by 40 percent and consider a sale or merger after a drug it was testing as a treatment for an increasingly common form of chronic liver disease failed to beat a placebo in a mid-stage clinical trial?the latest letdown in a number of trial failures. [?]